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Abstract
Background: Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase gene (DPYD) have a high risk to
experience severe drug-adverse effects following chemotherapy with fluoropyrimidine drugs such as 5-fluorouracil (5-FU) or
capecitabine. The pretreatment detection of this impairment of pyrimidine catabolism could prevent serious, potentially
lethal side effects. As known deleterious mutations explain only a limited proportion of the drug-adverse events, we
systematically searched for additional DPYD variations associated with enhanced drug toxicity.
Methodology/Principal Findings: We performed a whole gene approach covering the entire coding region and compared
DPYD genotype frequencies between cancer patients with good (n=89) and with poor (n=39) tolerance of a
fluoropyrimidine-based chemotherapy regimen. Applying logistic regression analysis and sliding window approaches we
identified the strongest association with fluoropyrimidine-related grade III and IV toxicity for the non-synonymous
polymorphism c.496A.G (p.Met166Val). We then confirmed our initial results using an independent sample of 53
individuals suffering from drug-adverse-effects. The combined odds ratio calculated for 92 toxicity cases was 4.42 [95% CI
2.12–9.23]; p (trend),0.001; p (corrected)=0.001; the attributable risk was 56.9%. Comparing tumor-type matched sets of
samples, correlation of c.496A.G with toxicity was particularly present in patients with gastroesophageal and breast cancer,
but did not reach significance in patients with colorectal malignancies.
Conclusion: Our results show compelling evidence that, at least in distinct tumor types, a common DPYD polymorphism
strongly contributes to the occurrence of fluoropyrimidine-related drug adverse effects. Carriers of this variant could benefit
from individual dose adjustment of the fluoropyrimidine drug or alternate therapies.
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Introduction
5-fluorouracil (5-FU) and orally available 5-FU prodrugs remain
a backbone of chemotherapy for locally advanced and metastatic
gastroesophageal, colorectal, and breast cancer [1–5], but can
result in toxic effects. Severe and unpredictable drug-adverse
events are mainly attributed to deficiency of the enzyme
dihydropyrimidine dehydrogenase (DPD). Due to its function as
initial and rate-limiting enzyme in the catabolism of pyrimidines,
DPD deactivates more than 80% of administered standard doses
of 5-FU [6–8]. The impairment of this pyrimidine degradation
pathway leads to toxic accumulation of the drug and, most likely,
concerns also patients treated with 5-FU-prodrugs like capecita-
bine [9]. Estimating a frequency of 3–5% of patients harbouring at
least a partial DPD deficiency, the pretherapeutical detection of
this metabolic dysfunction could prevent severe and unwanted side
effects due to fluoropyrimidine drugs.
After the characterization of the highly polymorphic human
dihydropyrimidine dehydrogenase gene (DPYD, MIM# 274270)
[10], rapid genetic testing has become feasible and numerous
sequence aberrations have been found in different ethnic
populations [11–16]. Specific DPYD variants result in a truncated
protein with clear deleterious effect to the enzyme including the
exon-14-skipping mutation IVS14+1g.a which has been consid-
ered as the most prevalent mutation in DPD deficient patients
[17]. However, such truncating mutations have appeared to
explain only a limited number of serious side effects attributed to
DPD deficiency. [18–20]. Moreover, only few missense mutations
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4003are known to directly interfere with protein structure, cofactor
binding or electron transfer of the DPD enzyme (e.g. c.703C.T;
c.2846A.T) [21–23]. Up to now, the impact of (common) non-
synonymous polymorphisms on fluoropyrimidine-induced toxicity
remains widely unclear and systematic association studies are
therefore mandatory.
In this context, the sequence variation c.496A.G (p.Met166-
Val) has been classified either as a mutation which is related to
DPD deficiency [24,25] or as a variant accompanied with normal
DPD activity in peripheral blood cells [26]. Here we are
presenting data showing a high prevalence of the c.496G risk
allele in cancer patients with increased toxic reactions compared to
patients with good tolerance of a fluoropyrimidine-containing
chemotherapy.
Methods
Objectives
In this study, we thoroughly evaluated the risk of several genetic
variants covering the entire DPYD gene for association with
enhanced toxicity during standard fluoropyrimidine-based che-
motherapy.
Participants
Our initial patient sample (n=128) consisted of Caucasian
subjects that had been diagnosed for breast, gastroesophageal and
colorectal cancer between 2003–2006 (Table 1) and who received
treatment with 5-FU-based therapy regimens (Table S1, support-
ing information) at the Klinikum rechts der Isar, Technische
Universita ¨t Mu ¨nchen; the Klinikum Hamburg-Eppendorf and at
other institutions in Germany.
For replication of our results, we included an additional cohort
of 53 cancer patients who had been independently genotyped
(DPYD exons 2, 6, 13 and 14) by the Center of Human Genetics
and Laboratory Medicine, Munich-Martinsried, Germany, during
2005–2007 because of acute drug-adverse reactions (Table 1,
cohort 2; and Table S1). Among these subjects, 14 had received
therapies containing the orally available 5-FU prodrug capecita-
bine (Xeloda, Hoffmann LaRoche Pharma, Switzerland, [27]).
In addition, a previously analyzed cohort of 157 healthy
individuals without a background of cancer [28] was considerably
enlarged up to 607 volunteers and genotyped for the variants
c.496A.G (rs2297595) and IVS10-15t.c.
Ethics
Written informed consent had been obtained from all
participating subjects and the study had been approved by the
local Ethics Committee.
Toxicity assessment
Side-effects that are typically associated with 5-FU treatment,
like neutropenia, thrombopenia, mucositis, diarrhea, nausea and
vomiting, neurotoxicity, cardiac toxicity, alopecia and hand-foot-
syndrome were documented within the first 3 cycles of the therapy.
The toxicity assessment was based on the National Cancer
Institute Common Toxicity Criteria Adverse Event reporting
guidelines (NCI-CTC AE, version 3.0) and was done without
knowledge of the genotyping results. No distinct therapy protocol
appeared to be particularly linked to higher unwanted toxicity.
PCR amplification and mutational analysis
DNA was prepared from frozen EDTA-blood samples using
standard techniques. The entire coding region of the DPYD gene
was amplified with 23 primer pairs corresponding to 23 exons and
the exon-intron-boundaries [28]. The detection of DPYD sequence
variants was carried out by denaturing HPLC analysis and
sequencing as previously described [29].
Statistical methods
The pairwise linkage disequilibrium measures, D9 and r
2, were
calculated using the software package Haploview [30].
Association between affection state (5-FU tolerance) of the
patient sample and genotypes was tested by logistic regression
analysis including age at treatment and sex as covariates. Different
single-marker association models were tested: no specific inheri-
tance model (considers all genotypic effects), the recessive model,
which contrasts one homozygote against the other pooled
genotypes (both alleles as recessive alleles were tested) and a trend
model which assumes an allele dose effect. Corrections for multiple
comparisons within each model were considered using a global
permutation test (1000 permutations). In addition, a two-marker
sliding window approach was performed to narrow down the
association signal.
Fisher’s exact test was applied to assess differences in the
distribution of polymorphisms with respect to toxicity in tumor-
type matched pairs of patient samples.
The proportion of the risk of side effects in the 496A.G carriers
that could be attributed to the G-allele (attributable risk in the
‘‘exposed’’) was calculated by the following formula: attributable
Table 1. Patient characteristics.
CONTROLS CASES WITH HIGH TOXICITY
Cohort 1 Cohort 2
Number of subjects: 89 39 53
Mean age at diagnosis: 58.2+/210.9 61.4+/210.2 62.2+/29.6
Gender:
Male 56 19 25
Female 33 20 28
Tumor:
Colorectal 15 14 35
Gastroesophageal 58 16 8
Breast 14 9 6
Not specified 2 0 4
Chemotherapy regimen:
PLF+/2Paclitaxel 38 10 1
OLF/FOLFOX 13 5 14
FOLFIRI 0 0 7
Mayo Protocol 1 5 1
5-FU/RTX 19 9 2
CMF 3 5 0
FEC 11 4 3
Xeloda+/2Oxaliplatin 0 0 14
Other/not available* 4 1 11
Toxicity (NCI-CTC-AE): Grade 0–II Grade III–IV Grade III–IV
Lethal outcome 0 2 0
*Chemotherapy contained 5-FU, but other components not specified.
Abbreviations: PLF, cisplatin, 5-fluorouracil, folinic acid; OLF/FOLFOX,
oxaliplatin, 5-fluorouracil, folinic acid; Mayo protocol, 5-fluorouracil, folinic acid;
FOLFIRI, irinotecan, 5-fluorouracil, folinic acid; CMF, cyclophosphamide,
methotrexate, 5-fluorouracil; FEC, 5-fluorouracil, epirubicin, cyclophosphamide.
doi:10.1371/journal.pone.0004003.t001
DPYD and FP-Related Toxicity
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effects in the combined group of heterozygous and homozygous
carriers of the G-allele and ‘Iu’ is the incidence of side effects in the
group with the major genotype (AA).
Results
Characteristics of the initial patient cohort
Based on common toxicity criteria guidelines (NCI-CTC AE,
version 3.0), we obtained a total of 39 cancer patients presenting
with grade III and IV toxicity after treatment with a 5-FU-
containing (poly)chemotherapy (Table S2, supporting informa-
tion). Thirty-seven of these individuals showed recovery from the
encountered adverse events following complete elimination of 5-
FU or corresponding dose reductions. Two patients had a fatal
outcome: One 62 year-old patient (Table S2, patient #26) with
rectal cancer developed severe neutropenia, mucositis and
diarrhea after 5-FU administration and died to the sequela of a
toxic shock syndrome. Another 76 year-old man (patient #17)
with locally advanced adenocarcinoma of the esophagogastric
junction died during the first 5-FU/oxaliplatin application. He
had reported severe angina pectoris and suffered a cardiac arrest.
Immediate resuscitation remained unsuccessful. Although autopsy
did not reveal structural damages of coronary arteries or heart
muscles, his death was attributed to 5-FU-induced cardiac toxicity,
possibly due to coronary spasm. In the majority of our recruited
patients (n=89), however, 5-FU-based chemotherapy was well
tolerated or caused only mild toxicity (NCI-CTC AE grading I–II).
Association of distinct polymorphisms with enhanced 5-
FU-induced toxicity
Scanning the entire reading frame of the DPYD gene in the above
described patient cohort, we identified 18 different single nucleotide
exchanges and one novel frameshift mutation, c.1109delTA
(p.Ile370LysfsX4), distributed across the entire DPYD gene
(Table 2). The linkage disequilibrium (LD) structure based on 18
SNPs shows considerable lowD9 and r
2 values with only two genetic
regions showing moderate LD (Fig. 1). This D9 and r
2 pattern may
indicate a large recombination-rich DNA interval comprising the
complete DPYD gene as suggested before [31,32].
Analysis of the DPYD genotypes revealed evidence of a strong
allele-dose-dependentassociationwiththeappearanceoftoxicityfor
two moderately correlated variants, IVS10-15t.c and c.496A.G
(r
2=0.68; p (trend),0.001), even after adjustment for multiple
testing (IVS10-15t.c: p (corrected)=0.009, odds ratio (OR)=3.88
[95% confidence interval 1.71–8.78]; c.496A.G: p (correct-
ed)=0.002; OR=4.58 [1.95–10.75]; Table 2). Regarding the
two-marker sliding window approach the strongest association
signals were observed for those haplotype combinations which
included the marker c.496A.G (e.g. marker combination
c.496A.G and IVS5+18 g.a: haplotype G/G; frequency in
patients with and without toxicity; 0.256 vs. 0.088; p=0.0003). This
suggeststhatthesingle markerassociation signal ismainlyduetothe
functional SNP c.496A.G causing a non-synonymous amino acid
substitution (p.Met166Val) at a highly conserved position and
within a conserved three-dimensional environment [25,33].
In the studied patient cohort, the attributable risk to suffer from
severe drug-adverse effects due to the 496G-allele was 56.9%.
Further clinical support of the relevance of this polymorphism with
respect to enhanced toxicity may come from the patient samples:
one case of cardiac death concerned a heterozygous G-allele
carrier (patient #17, Table S2) and all homozygous carriers of the
G-allele (patients #16, 23, 31) fell into the subgroup of patients
with enhanced toxicity. The considerable lower frequency of the
c.496G-allele in patients with good tolerance of 5-FU (0.082) was
identical with the population-based control group (0.081) consist-
ing of 607 healthy individuals (Table 2).
Reevaluation of the association data with an additional
patient cohort
To corroborate our findings we included a second cohort of 53
patients which has been collected and analyzed independently
(cohort 2, Table 2). All patients had reacted with severe drug-
adverse events following treatment with a 5-FU- or capecitabine-
based chemotherapy regimen. The c.496A.G minor allele
frequency of this second cohort (0.23) showed no relevant
difference compared to the initial toxicity group (0.26). In this
context it is interesting that three c.496G allele carriers
encountered severe toxicity (mainly diarrhea and hand-foot-
syndrome) after application of the orally available 5-FU prodrug
capecitabine, which resulted in cessation of the chemotherapy in
two individuals. These observations may emphasize a risk for drug
intolerance due to DPD involvement in chemotherapy regimens
using capecitabine [9].
Analysis of the combined patient sample with toxicity (initial
and second cohort; n=92) yielded a significant dose-dependent
association for the DPYD marker c.496A.G( p (trend),0.001; p
(corrected)=0.001; OR=4.42 [2.12–9.23]. In addition, no signif-
icant association with fluoropyrimidine-related side effects was
observed for the other DPYD polymorphisms, gender and age at
treatment.
Incidence of c.496A.G in tumor type-matched sets of
samples
Since distinct DPYD polymorphisms could be correlated with a
particular type of tumor, we additionally re-evaluated our
association data in tumor-type matched sets of patients (Table 3).
Gastroesophageal and breast cancer patients reflected the results
obtained in toxicity and control cases of the whole patient
population. No association of c.496A.G or IVS10-15t.c with
enhanced toxicity was achieved for colorectal carcinoma cases,
although a trend towards higher prevalence of these variants was
linked to side effects following a fluoropyrimidine/platinum
therapy (e.g. c.496A.G frequency in toxicity versus control
group: 0.29 versus 0.17; p=0.378).
Low frequency of clear deleterious mutations in our
patient population
The well-described exon-14-skipping mutation IVS14+1g.a
which is related to DPD deficiency occurred in only five of all 92
cases with toxic side effects. This splice-site mutation was not
observed in patients with good tolerance of a fluoropyrimidine
therapy. Another yet undescribed truncating mutation (c.1109del-
TA) was discovered in a patient who suffered fatal toxicity during
the 1
st cycle of 5-FU monotherapy (patient #26, Table S2). The
previously unknown frameshift mutation in exon 10 leads to a stop
codon at position 374. Finally, the missense mutation 2846 A.T
(p.Asp949Val), which is assumed to interfere with iron-sulfur-
cluster formation and thus, with the electron transfer during the
catalytic reaction of the enzyme DPD [21], was only found in one
individual with severe enterotoxicity of grade IV (patient #29,
Table S2).
Discussion
Sequence variations in the DPYD gene have been shown to
influence the breakdown of the common anticancer drug 5-FU
DPYD and FP-Related Toxicity
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application in cancer patients. Moreover, the integrity of the 5-FU
degradation pathway appears to be of similar importance
concerning the application of newly introduced fluoropyrimidine
drugs which are intracellularly converted into 5-FU [9,34,35].
Thus, these observations warrant systematic detection of DPD-
deficient patients prior to fluoropyrimidine administration.
However, a practical and reliable pretreatment test for DYPD
variants or mutations has not been available so far due to the high
genetic variability of the DPYD coding region and the rare
occurrence of clear deleterious mutations, at least in Caucasian
populations [18,19]. For this reason, several functional methods
designed for the rapid prediction of a (partial) DPD deficiency
such as the 2-
13C-uracil breath test [36] or the determination of
plasmatic uracil/dihydrouracil ratios [34,37,38] have been
introduced in the meantime. Mercier and colleagues reported
very recently, that prospective evaluation of the functional DPD
status followed by corresponding 5-FU dose tailoring led to a 2-
fold decrease in the occurrence of severe toxicities [39].
Nevertheless, these methods have not found broad application in
clinical routine so far [40], not least because these kind of analyses
require a special equipment. In addition, a lack of correlation
between DPD activity measurements and 5-FU toxicity was
assumed [41]. Clearly, methodologies based on genetic testing for
clinically relevant SNPs would offer the simplest way to identify
patients at the highest risk of potentially life-threatening drug-
adverse events.
With respect to the development of a genetic test, we conducted a
systematic analysis of the coding region of the gene DPYD and
compared the incidence of commonly found SNPs between cancer
patients with good and with poor tolerance of a fluoropyrimidine-
based chemotherapy. We observed a significant allele-dose-
dependent association of the non-synonymous sequence aberration
c.496A.G (p.Met166Val) with the phenotype of enhanced toxicity
ofgrade III/IV.Themethionine-valine exchangeresulting from the
c.496A.G transition has been already implicated in a deleterious
effect in DPD deficient patients [24,25], but conflicting results have
been reported for its influence on enzyme activity [26]. While DPD
activity measured in peripheral blood mononuclear cells might be
unrelated to 5-FU toxicity according to a study by Di Paolo et al.
Figure 1. Linkage disequilibrium (LD) structure based on 18 DPYD variants. Pairwise LD measures (r
2) calculated with the software package
Haploview [ref. 30] are shown. The strongest LD region is highlighted.
doi:10.1371/journal.pone.0004003.g001
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strongly speaks in favour of a biological relevance of this amino acid
change [33]. Most strikingly, carriers of the c.496A.G genotype
constituted more than 43% of the individuals with severe drug-
adverse effects in our study. In contrast to this high prevalence, the
classical exon-14-skipping mutation IVS14+1g.a( DPYD*2A)
occurred in only five patients (5.4%) of overall 92 toxicity cases.
Moreover, another yet undescribed truncating mutation, c.1109del-
TA (p.Ile370LysfsX4), and a putative deleterious missense mutation
(c.2846A.T) were detected each once in the studied patient
population. Thus, compared to other recent publications which
reported either marginal predictive potential [19,20] or a reduction
of severe adverse effects of up to 27% by prospective genotyping for
the mutations IVS14+1g.a and/or c.2846A.T [40,15], the
detection of a more frequent polymorphism associated with an
elevated risk for fluoropyrimidine intolerance would help to identify
much more risk patients. These individuals could benefit from
careful individual dose adaptation of 5-FU or 5-FU prodrugs.
A potential bias of our study could have been introduced by
association of c.496A.G with a certain tumor type. In this context,
nodiscrepancywith resultsobtained inthewholepatient population
was obvious regarding breast or gastroesophageal cancers. In
addition, the incidence of c.496A.G in the respective control cases
withoutenhancedtoxicitydidnotexceedthefrequencymeasuredin
607 healthy individuals speaking against a relation of c.496A.G
with the development of these cancers. In contrast to these results,
no significant correlation of c.496A.G with toxicity could be
determined for colorectal cancer patients yet because the sequence
aberration displayed increased incidence (compared to healthy
volunteers) in toxicity as well as in control cases. However, due to
the rather small number of control cases (n=15) which were
available for this type of cancer, the amount of 496G-allele carriers
in the control group might have been overestimated and needs
further evaluation with higher case numbers.
On the other side, the different results obtained with colorectal
cancer patients could explain the discrepancy between our findings
and those of Schwab et al. [20] concerning a major role of
c.496A.G in severe drug-adverse effects. The recent study by
Schwab et al. which suggested a limited role of genetic factors for
severe 5-FU toxicity relies mainly on patients with colorectal
carcinoma. Another reason for the different observations may be
linked to the type of treatment of the patients, as Schwab et al.
have restricted their clinical trial to 5-FU monotherapy. Whereas
only 19% of gastroesophageal cancers were treated with 5-FU+/
2folinic acid in our study, 45% of colorectal cancer patients
received such treatment. Accordingly, less pronounced association
with the variant 496A.G was found – although at low case
numbers - for 5-FU alone or with chemoradiation yielding 496G-
allele frequencies of 0.14 (n=11) versus 0.105 (n=19) in cancer
patients with and without severe drug-adverse events. However, a
high prevalence of the c.496A.G genotype was confirmed in our
patients with severe toxicity regarding 5-FU/ platinum or
anthracycline-containing regimens (frequency of 496G-alleles in
patients with and without severe toxicity: 0.25 (n=30) versus 0.08
(n=51) for 5-FU/folinic acid/platinum drug therapies; 0.43
(n=7) versus 0.05 (n=10) for FEC treatment). These data may
suggest that the influence of c.496A.G is more obvious in the
presence of additional, drugs.
Since relatively high DPD activity has been reported for
c.496A.G carriers by Johnson et al. [26] we cannot rule out that
the severe c.496A.G-associated phenotype is due to a cumulative
effect caused by toxic fluoropyrimidine catabolites [42] and
cytotoxicity of other components of the polychemotherapy [43].
Nevertheless, our data obtained on a high number of toxicity cases
(n=92), comparable to the study by Schwab et al., show a clear,
clinically important association which reached high significance in
gastroesophageal and breast cancers.
With respect to the complexities in pharmacogenomics [44],
evaluation of different therapy regimens and tumor types may lead
to a better understanding of the role of genetic factors in
fluoropyrimidine-related drug-adverse-events. Gene chip analyses
for the detection of relevant DPYD variants as previously
introduced by Zhang et al. [45] might then be the best choice in
a future clinical setting.
Limitations
Although this initial study relies on a relatively high number of
patients with severe toxicity, case numbers are still limited.
Analysis of further cases with toxic side effects is now utterly
required taking also into account the specific type of tumor and
treatment protocol.
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